FDA approves new Kisunla dosing regimen to lower ARIA-E risk
A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.| Alzheimer's News Today
A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.| Alzheimer's News Today
Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.| Alzheimer's News Today
The new ApoE4 Alzheimer's Alliance plans to advocate on behalf of patients with this gene variant for more supportive U.S. policies.| Alzheimer's News Today
Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild cognitive issues.| Alzheimer's News Today
Early menopause and poor brain-connection health may interact to increase Alzheimer's disease risk in women, a study found.| Alzheimer's News Today
Early-onset Alzheimer's is a rare form of dementia that occurs between ages 30 and 60, and may affect several members of a single family.| Alzheimer's News Today
Recruitment has begun at the first clinical site of START, a Phase 2 study evaluating Elayta in adults with early Alzheimer's disease.| Alzheimer's News Today
Anavex is preparing meetings with regulatory authorities in the U.S., Europe, and Asia-Pacific to discuss Anavex 2-73’s potential approval.| Alzheimer's News Today
Alpha Cognition’s ALPHA-1062 for Alzheimer’s showed efficacy in a trial as a bioequivalent substitute for the approved therapy Razadyne.| Alzheimer's News Today
Alpha Cognition’s oral tablet ALPHA-1062 may be a bioequivalent to galantamine hydrobromide – sold as Razadyne – for Alzheimer’s disease.| Alzheimer's News Today
The immunotherapy Leqembi, formerly BAN2401, is now FDA-approved for slowing cognitive decline in patients with Alzheimer's disease.| Alzheimer's News Today
Kisunla (donanemab-azbt) is an antibody-based therapy approved in the U.S. for adults with early symptomatic Alzheimer’s disease.| Alzheimer's News Today
Diagnosis of Alzheimer's disease involves assessing patients' medical history, symptoms, lab tests, and using brain imaging to rule out other conditions.| Alzheimer's News Today
Columnist Ray Burow, reflecting on caregiving for her late mother, ponders if it's sometimes OK to lie to a person with Alzheimer's disease.| Alzheimer's News Today
The Phase 2 study will further assess SNK01's safety and its efficacy in about 30 patients who'll receive it every three weeks up to a year.| Alzheimer's News Today
Columnist Ray Burow can attest to the challenges that sandwich generation caregivers face, but says her children learned valuable lessons.| Alzheimer's News Today
Learn more about Alzheimer's disease, the most common cause of dementia and an irreversible, progressive neurological disorder.| Alzheimer's News Today
